机器学习模型预测炎症性肠病患者复发性艰难梭菌感染
本研究利用2013至2021年成人炎症性肠病(IBD)合并艰难梭菌感染(CDI)患者数据,采用XGBoost机器学习模型开发并验证RecurCDI-IBD预测模型,主要结局为初始CDI发作后60天内复发性CDI(rCDI)。模型预测rCDI的准确率为80.05%,曲线下面积(AUC)为0.88,关键预测特征包括IBD亚型、性别、特定药物(如类固醇和抗TNF药物)及合并症(如慢性肺病和肾病)。
要点
- RecurCDI-IBD模型预测IBD患者60天内rCDI的准确率为80.05%,AUC为0.88。
- 关键预测特征包括IBD亚型、性别、类固醇和抗TNF药物使用及慢性肺病和肾病。
- 模型需更大样本和前瞻性外部验证以确认泛化性和临床适用性。
核心结论
- RecurCDI-IBD模型在识别IBD患者rCDI高风险方面表现出良好的区分能力,精确率和召回率均衡。
研究设计与样本
- 研究收集2013至2021年确诊CDI且有IBD病史的成人患者数据,使用XGBoost梯度提升机学习模型训练二分类模型。
- 特征工程包括人口学数据(年龄和性别)、临床数据(IBD亚型、药物使用和合并症)及实验室数据。
- 主要结局为初始CDI发作后60天内发生rCDI。
主要发现
- RecurCDI-IBD模型预测rCDI的准确率为80.05%,AUC为0.88。
- 关键预测特征包括IBD亚型、性别、特定药物(如类固醇和抗TNF药物)及合并症(如慢性肺病和肾病)。
临床怎么用
- 该模型有潜力通过数据驱动方法支持临床风险分层,识别IBD患者中rCDI高风险个体以实施针对性干预。
- 临床使用前需进一步开展更大规模、更多样化队列的前瞻性外部验证以确认泛化性并优化临床适用性。
局限性
- 需进一步研究纳入更大和更多样化的队列并进行前瞻性外部验证,以确认模型的泛化性并优化临床适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Clostridioides difficile infection (CDI) presents a significant challenge in patients with inflammatory bowel disease (IBD), with high recurrence rates and complications. Predicting recurrent CDI (rCDI) in patients with IBD is crucial for implementing targeted interventions to improve patient outcomes. This study aimed to develop and validate a predictive model (RecurCDI-IBD) using supervised machine learning to identify patients with IBD at high risk of developing rCDI. METHODS: Data were collected from adult patients with IBD diagnosed with CDI between 2013 and 2021. Inclusion criteria included adult patients with a confirmed diagnosis of CDI and a history of IBD. The Gradient Boosting Machine learning model (XGBoost) was used to train a binary classification model. Feature engineering included demographic data (age and sex), clinical data (IBD subtype, medication use, and comorbidities), and laboratory data. The primary outcome was the occurrence of rCDI within 60 days of the initial CDI episode. RESULTS: The RecurCDI-IBD model achieved an accuracy of 80.05% and an Area Under the Curve of 0.88 for predicting rCDI. Key predictive features included IBD subtype, sex, specific medications (such as steroids and anti-TNF agents), and comorbidities (such as chronic pulmonary and renal disease). DISCUSSION: The RecurCDI-IBD model demonstrates good discriminatory ability with balanced precision and recall in identifying patients with IBD at higher risk for rCDI. These findings highlight the potential of data-driven approaches to support clinical risk assessment. Further studies incorporating larger and more diverse cohorts and prospective external validation are needed to confirm generalizability and optimize clinical applicability.
引用
- Tariq R, Sethi A, Arunachalam S, et al. Machine Learning Model Predicts Recurrent Clostridioides difficile Infection in Patients With Inflammatory Bowel Disease (Recur CDI-IBD). Am J Gastroenterol. 2026. PMID: 41562450. doi:10.14309/ajg.0000000000003922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。